Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03415685 · ClinicalTrials.gov registry record · NA

Lutronic PicoPlus Exploratory Clinical Trial

A NA study, sponsored by CynosureLutronic.

Terminated
Registry status
NA
Development phase
39
Enrollment target

NCT03415685: Clinical Trial NA study, sponsored by CynosureLutronic.

NCT03415685 is a NA study that was terminated before completion, run by CynosureLutronic. The registered enrollment target is 39 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03415685, a NA study, was terminated before completion, sponsored by CynosureLutronic.

TERMINATED
Registry status
NA
Development phase
39 participants
Enrollment target

Study Summary

This study will evaluate the use of the Lutronic PicoPlus for treatment of dermatological conditions such as unwanted tattoos and benign pigmented lesions.

Primary Outcome

Overall aesthetic improvement based on completion of the Physician's Global Assessment of Improvement Scale. Physician evaluators will review study photos post-final treatment, and rate the degree of tattoo clearing or reduction in benign pigmentation observed in the subject's treated area using the following definitions: 3 = Very significant or complete clearing (75-100%) 2 = Significant clearing (50-74%) 1 = Moderate clearing (25-49%) 0 = Mild or no clearing (0-24%)

Interventions

  • DEVICE PicoPlus laser system

Trial Details

FieldValue
Enrollment Target 39 participants
Start Date 2017-10-12
Est. Completion 2018-10-03
Phase NA
CynosureLutronic

9 total trials

Why NCT03415685 stopped before completion

NCT03415685 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).

The record links to 0 conditions, and to 1 intervention - of which PicoPlus laser system is the first listed.

NCT03415685 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03415685 about?

NCT03415685 is a clinical study titled "Lutronic PicoPlus Exploratory Clinical Trial". This study will evaluate the use of the Lutronic PicoPlus for treatment of dermatological conditions such as unwanted tattoos and benign pigmented lesions.

What is the current status of trial NCT03415685?

This trial is currently terminated. It is a NA study. The enrollment target is 39 participants. The study started on 2017-10-12. Estimated completion is 2018-10-03.

What interventions are being tested in trial NCT03415685?

The interventions under investigation include: PicoPlus laser system (DEVICE).

Who is sponsoring clinical trial NCT03415685?

This trial is sponsored by CynosureLutronic, which has 9 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03415685's enrollment target sits among peer trials

39 1536th of 2000 higher than 463 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03465592 · 39 participants · Phase 1

    Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma

  • NCT03961776 · 39 participants

    Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems

  • NCT04050280 · 39 participants · Phase 2

    CLAG-GO for Patients With Persistent, Relapsed or Refractory AML

  • NCT04190862 · 39 participants · Phase 1

    E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03415685, the US trial registry maintained by the National Library of Medicine. NCT03415685 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.